Related Experiment Video

Updated: Jan 30, 2026

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.5K

Safety and Tolerability of c-MET Inhibitors in Cancer

Alberto Puccini1,2, Nagore I Marín-Ramos3, Francesca Bergamo4

  • 1Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Suite 5410, Los Angeles, CA, 90033, USA.

Drug Safety
|January 17, 2019
PubMed

Insights

Aberrant hepatocyte growth factor receptor (c-MET) signaling drives cancer. While approved c-MET inhibitors show promise, ongoing research explores novel inhibitors and combinations for improved cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant signaling of the hepatocyte growth factor receptor (c-MET) and its ligand (HGF) is implicated in cancer progression and invasion.
  • c-MET inhibitors have demonstrated pre-clinical and early clinical anti-tumor activity, but Phase III trial results have often been negative.

Purpose of the Study:

  • To provide an overview of c-MET inhibition in cancer.
  • To discuss the efficacy of approved c-MET inhibitors and novel agents under development.
  • To examine targeted combination strategies and their safety profiles.

Main Methods:

  • Review of pre-clinical and clinical trial data on c-MET inhibitors.
  • Analysis of approved c-MET inhibitors (cabozantinib, crizotinib).
  • Evaluation of novel c-MET inhibitors (monoclonal antibodies, small molecule tyrosine kinase inhibitors) and combination strategies.

Main Results:

  • Two small molecule c-MET inhibitors are approved for specific cancer types.
  • Several novel c-MET inhibitors and combination therapies are under investigation.
  • Focus on safety and tolerability of c-MET targeted agents.

Conclusions:

  • c-MET inhibition is a key strategy in oncology, with ongoing development of new agents and combinations.
  • Understanding the efficacy and safety of these novel therapies is crucial for advancing cancer treatment.
  • Further research is needed to overcome challenges observed in Phase III trials.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K

Related Concept Videos

Survey Safety01:28

Survey Safety

Surveying near highways, rough terrain, or power lines involves significant risks. Working along highways is particularly dangerous and requires the use of warning signs and flagmen. It is safest to avoid working directly on roads and use offsets whenever possible. When highway work is unavoidable, it must follow all safety guidelines. Surveyors should wear bright clothing, such as orange reflective vests, to ensure visibility to motorists, coworkers, and hunters. In construction zones, wearing...
390
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Household Wiring And Electrical Safety01:13

Household Wiring And Electrical Safety

Companies that supply power to most modern households use three conductors, typically called a three-wire line. While one is neutral, the other two are both at 120 V but with opposite polarity, giving a voltage of 240 V between them. With a three-wire line, high-power appliances that require 240 V, such as electric stoves and clothes dryers, are linked between the two hot lines. 120 V appliances can be connected between the neutral and either of the hot lines. The neutral side, which is always...
1.7K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
667
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K